北美专家意见:肝移植中的肌少症
肌少症是肝硬化常见特征,与不良结局相关。北美肝移植肌少症工作组基于文献证据提出:所有评估肝移植的肝硬化患者应考虑肌少症评估,CT测骨骼肌指数是研究最充分的技术,男性SMI<50 cm²/m²、女性<39 cm²/m²为已验证定义。管理需营养、运动及必要药物多管齐下。
要点
- 所有评估肝移植的肝硬化患者应考虑肌少症评估。
- CT测骨骼肌指数是研究最充分的肌少症评估技术。
- 肌少症定义:男性SMI<50 cm²/m²,女性<39 cm²/m²。
核心结论
- 肌少症是肝硬化患者不良结局的主要指标,包括生活质量差、肝功能失代偿、等待肝移植患者死亡、住院和ICU时间延长、移植后感染发生率增高及总体医疗费用增加。
- 所有评估肝移植的肝硬化患者应考虑肌少症评估。
- 肌少症管理需多管齐下,包括营养、运动及认为必要的额外药物治疗。
- 未来研究应评估营养管理联合运动项目使肌少症恢复是否可持续,以及肌肉量改善如何与临床结局改善相关。
研究设计与样本
- 北美肝移植肌少症工作组汇集专家,利用医学文献证据回答肝移植中肌少症的突出问题。
主要发现
- 肌肉量是肝移植结局的重要预测因素,但最佳评估方式、肌少症最佳截断值、评估理想时机和频率以及如何将肌少症概念纳入临床决策等问题仍存。
- CT测骨骼肌指数是肝硬化患者肌少症评估中研究最充分的技术。
- 男性SMI<50 cm²/m²、女性<39 cm²/m²为肝硬化患者肌少症已验证定义。
关键数值与推荐
- 肌少症定义:男性SMI<50 cm²/m²,女性<39 cm²/m²。
- CT测骨骼肌指数为肝硬化患者肌少症评估中研究最充分的技术。
临床怎么用
- 所有评估肝移植的肝硬化患者应考虑肌少症评估。
- 肌少症管理采用多管齐下方法,包括营养、运动及认为必要的额外药物治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contributes significantly to morbidity and mortality in this population. Sarcopenia is a main indicator of adverse outcomes in this population, including poor quality of life, hepatic decompensation, mortality in patients with cirrhosis evaluated for liver transplantation (LT), longer hospital and intensive care unit stay, higher incidence of infection following LT, and higher overall health care cost. Although it is clear that muscle mass is an important predictor of LT outcomes, many questions remain, including the best modality for assessing muscle mass, the optimal cut-off values for sarcopenia, the ideal timing and frequency of muscle mass assessment, and how to best incorporate the concept of sarcopenia into clinical decision making. For these reasons, we assembled a group of experts to form the North American Working Group on Sarcopenia in Liver Transplantation to use evidence from the medical literature to address these outstanding questions regarding sarcopenia in LT. We believe sarcopenia assessment should be considered in all patients with cirrhosis evaluated for liver transplantation. Skeletal muscle index (SMI) assessed by computed tomography constitutes the best-studied technique for assessing sarcopenia in patients with cirrhosis. Cut-off values for sarcopenia, defined as SMI < 50 cm2 /m2 in male and < 39 cm2 /m2 in female patients, constitute the validated definition for sarcopenia in patients with cirrhosis. Conclusion: The management of sarcopenia requires a multipronged approach including nutrition, exercise, and additional pharmacological therapy as deemed necessary. Future studies should evaluate whether recovery of sarcopenia with nutritional management in combination with an exercise program is sustainable as well as how improvement in muscle mass might be associated with improvement in clinical outcomes.
引用
- Carey EJ, Lai JC, Sonnenday C, et al. A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation. Hepatology. 2019. PMID: 31220351. doi:10.1002/hep.30828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。